1. Dexmedetomidine protects cells from Angiotensin II-induced smooth muscle cell phenotype switch and endothelial cell dysfunction
   Min Dai et al, 2022, Cell Cycle CrossRef
2. Bioinformatics-based identification of lipid- and immune-related biomarkers in abdominal aortic aneurysms
   Yuejin Li et al, 2023, Heliyon CrossRef
3. Dexmedetomidine Alleviates Abdominal Aortic Aneurysm by Activating Autophagy Via AMPK/mTOR Pathway
   Qi Yu et al, 2023, Cardiovasc Drugs Ther CrossRef
4. miRNA Regulation of Cell Phenotype and Parietal Remodeling in Atherosclerotic and Non-Atherosclerotic Aortic Aneurysms: Differences and Similarities
   Sonia Terriaca et al, 2024, IJMS CrossRef
5. Therapeutic potential of natural products and underlying targets for the treatment of aortic aneurysm
   Wenwen Zhao et al, 2024, Pharmacology & Therapeutics CrossRef
6. Roles and Mechanisms of miRNAs in Abdominal Aortic Aneurysm: Signaling Pathways and Clinical Insights
   Haorui Zhang et al, 2024, Curr Atheroscler Rep CrossRef
7. The relationship between dexmedetomidine administration and prognosis in patients with sepsis-induced coagulopathy: a retrospective cohort study
   Hongyu Huang et al, 2024, Front. Pharmacol. CrossRef